Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Selim
Magdy
M
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. mselim@bidmc.harvard.edu
D001241:Aspirin / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000150:complications; D000077144:Clopidogrel; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin